These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39269567)

  • 1. Understanding the Sequelae of Invasive Meningococcal Disease in the United States.
    Marshall GS; McCormick ZL; Johns JS; Verduzco-Gutierrez M; Herrera-Restrepo O; Harrison LH
    Infect Dis Ther; 2024 Nov; 13(11):2213-2220. PubMed ID: 39269567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.
    Begum S; Herrera-Restrepo O; Rolland C; Purushotham S; Andani A; Shah H; Kocaata Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406613. PubMed ID: 39373020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential public health impact of a
    Huang L; Snedecor SJ; Balmer P; Srivastava A
    Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.
    Marshall GS; Fergie J; Presa J; Peyrani P
    Infect Dis Ther; 2022 Jun; 11(3):937-951. PubMed ID: 35357651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers.
    Olbrich KJ; Müller D; Schumacher S; Beck E; Meszaros K; Koerber F
    Infect Dis Ther; 2018 Dec; 7(4):421-438. PubMed ID: 30267220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing patterns of invasive meningococcal disease and future immunization strategies.
    Taha MK; Bekkat-Berkani R; Abitbol V
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186111. PubMed ID: 37017273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal Vaccination of Adolescents in the United States: Past Successes and Future Considerations.
    Presa J; Findlow J; Zimet GD
    J Adolesc Health; 2024 Jun; 74(6):1068-1077. PubMed ID: 38430074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review.
    Shen J; Begum N; Ruiz-Garcia Y; Martinon-Torres F; Bekkat-Berkani R; Meszaros K
    BMC Public Health; 2022 May; 22(1):1078. PubMed ID: 35641955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM).
    Shen J; Bouée S; Aris E; Emery C; Beck EC
    Infect Dis Ther; 2022 Feb; 11(1):249-262. PubMed ID: 34791633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.
    Marten O; Koerber F; Bloom D; Bullinger M; Buysse C; Christensen H; De Wals P; Dohna-Schwake C; Henneke P; Kirchner M; Knuf M; Lawrenz B; Monteiro AL; Sevilla JP; Van de Velde N; Welte R; Wright C; Greiner W
    Health Qual Life Outcomes; 2019 May; 17(1):87. PubMed ID: 31118091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive meningococcal disease in older adults: current perspectives and call for action.
    Weil-Olivier C; Taha MK; Leng S; Dinleyici EC; Bonanni P; Moya E; Leischker A; Yezli S
    Eur Geriatr Med; 2024 Jun; 15(3):729-741. PubMed ID: 38709380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
    J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.